Therapeutic Value of miRNAs in Coronary Artery Disease
Table 2
Therapeutic role of miRNAs in atherosclerosis.
miRNAs
Effects and targets
References
Mimic-miR-30c
Reduces hyperlipidemia and atherosclerosis development through decreasing lipid synthesis and apolipoprotein B (APOB) secretion by inhibiting microsomal transfer protein (MTP) activity in ApoE−/− mice
Markedly reduces atherosclerosis in human aortic endothelial cells (HAECs) via downregulation of the inflammatory NLRP3 protein expression and forkhead box O3 (FOXO3)
Increases HDL-cholesterol levels and prevents dyslipidemia and atherosclerosis progression through angiopoietin-like protein 8 (ANGPTL8) in liver cells
Increases HDL levels, enhances cholesterol efflux, inhibits inflammation and the transformation of macrophages into foam cells, and reduces atherosclerosis plaque progression in ApoE−/− mice
Reduces atherosclerosis lesion formation in ApoE−/− mice by reducing inflammatory responses of macrophages and enhances cholesterol efflux through targeting suppressor of cytokine signaling 1 (SOCS-1)
Suppresses NF-κB-linked proteins that include tissue factor, vascular cell adhesion molecule-1, E-selectin, and intercellular adhesion molecule-1 and decreases arterial thrombus formation by ~73% via caspase recruitment domain family member 10 (Card10) proteins
Delays unstable plaque progression in patients with unstable coronary artery disease by inhibiting endothelial cell proliferation and migration and angiogenesis through STAT3 transcriptional activity in EA.hy926 cells